UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED
PURSUANT
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(a)
Under the Securities Exchange Act of 1934
(Amendment No. 16)*
Abcam plc
(Name of Issuer)
Ordinary Shares
(Title of Class of Securities)
000380204
(CUSIP Number)
Jonathan Milner
Honey Hill House, 20 Honey Hill
Cambridge CB3 0BG
With copies to:
Richard M. Brand
Cadwalader, Wickersham & Taft LLP
200 Liberty Street
New York, NY 10281
212-504-6000 |
Michael Newell
Cadwalader, Wickersham & Taft LLP
100 Bishopsgate
London EC2N 4AG
44 (0) 20 7170 8540 |
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
October 23, 2023
(Date of Event Which Requires Filing of This
Statement)
If the filing person
has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. x
Note: Schedules filed in paper
format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom
copies are to be sent.
| * |
The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page. |
The information required on the remainder of
this cover page shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
| 1 |
|
NAME OF REPORTING PERSON
Dr. Jonathan Milner |
| 2 |
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ¨ (b) x
|
| 3 |
|
SEC USE ONLY
|
| 4 |
|
SOURCE OF FUNDS
PF (See Item 3) |
| 5 |
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) OR 2(e) ¨
|
| 6 |
|
CITIZENSHIP OR PLACE OF ORGANIZATION
United Kingdom |
Number of
shares
beneficially
owned by
each
reporting
person
with |
|
7 |
|
SOLE VOTING POWER
11,767,6001 |
| |
8 |
|
SHARED VOTING POWER
2,410,8022 |
| |
9 |
|
SOLE DISPOSITIVE POWER
11,767,6001 |
| |
10 |
|
SHARED DISPOSITIVE POWER
2,410,8022 |
| 11 |
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
14,178,4021, 2 |
| 12 |
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES ¨
|
| 13 |
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
6.16%* |
| 14 |
|
TYPE OF REPORTING PERSON
IN |
| |
|
|
|
|
|
|
* All percentage calculations set forth herein are based upon the
aggregate of 230,151,118 Ordinary Shares as of October 2, 2023, as reported in Exhibit 99.2 of the Issuer’s Report of Foreign Private
Issuer on Form 6-K Filed with the SEC on October 5, 2023.
1 Includes 11,700,200 Ordinary Shares directly held by
the Reporting Person and 67,400 shares directly held by the Reporting Person through American Depository Shares representing, each, one
Ordinary Share (“ADS”).
2 Includes 399,382 ADSs held by the Reporting Person’s
spouse, 1,977,967 ADSs held by three limited companies over which the Reporting Person exercises investment discretion and 33,453 ADSs
held by a charitable trust to which the Reporting Person is a trustee and signatory. The Reporting Person disclaims beneficial ownership
over the shares beneficially owned by his spouse, except to the extent of his pecuniary interest therein.
This Amendment No. 16 to
Schedule 13D (this “Amendment No. 16”) amends and supplements the Schedule 13D filed on May 1, 2023, as amended and supplemented
on May 18, 2023, May 30, 2023, June 5, 2023, June 6, 2023, June 12, 2023, June 20, 2023, June 21, 2023, June 23, 2023, June 27, 2023,
August 16, 2023, September 14, 2023, September 28, 2023, October 10, 2023, October 12, 2023 and October 16, 2023 (the “Original
13D,” and as amended and supplemented by this Amendment No. 16, the “Schedule 13D”) by the Reporting Person, relating
to the Ordinary Shares of the Issuer. Except as specifically provided herein, this Amendment No. 16 does not modify any of the information
previously reported in the Schedule 13D. Capitalized terms not defined in this Amendment No. 16 shall have the meaning ascribed to them
in the Original 13D.
The purpose of this Amendment No. 16 is to update
the disclosure in Items 4, 5 and 7 of the Schedule 13D as hereinafter set forth.
| ITEM 1. |
SECURITY AND ISSUER |
This statement on Schedule
13D relates to the Ordinary Shares of the Issuer. The principal executive offices of the Issuer are located at Discovery Drive, Cambridge
Biomedical Campus, Cambridge, CB2 0AX, United Kingdom.
| ITEM 2. |
IDENTITY AND BACKGROUND |
(a), (f) This statement is being filed by Dr.
Jonathan Milner, a citizen of the United Kingdom.
(b) The address of the Reporting Person is Honey
Hill House, 20 Honey Hill, Cambridge, CB3 0BG.
(c) The Reporting Person’s
principal occupation is as an investor and executive in life sciences companies.
(d), (e) During the last
five years, the Reporting Person (i) has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors)
and (ii) was not a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such
proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities
subject to, federal or state securities laws or finding any violations with respect to such laws.
| ITEM 4. |
PURPOSE OF TRANSACTION |
Item 4 is hereby amended to add the following:
On October 23, 2023, the Reporting Person published
a press release, as set forth more fully in Exhibit 99.25 hereto.
| ITEM 5. |
INTEREST IN SECURITIES OF THE ISSUER |
(a) The Reporting Person is the holder of 11,700,200
Ordinary Shares and 67,400 ADSs. In addition, the Reporting Person may be deemed to share beneficial ownership over (a) 1,977,967 ADSs
beneficially owned by three limited companies over which the Reporting Person exercises investment discretion, (b) 399,382 ADSs beneficially
owned by the Reporting Person’s spouse and (c) 33,453 ADSs held by a charitable trust to which the Reporting Person is a trustee
and signatory. The Reporting Person disclaims beneficial ownership over the shares beneficially owned by his spouse, except to the extent
of his pecuniary interest therein. The shares described in this Item 5 represent approximately 6.16% of the outstanding Ordinary
Shares.
(b)
| |
(i) |
Sole power to vote or to direct the vote: 11,767,600 |
| |
(ii) |
Shared power to vote or direct the vote: 2,410,802 |
| |
(iii) |
Sole power to dispose or to direct the disposition of: 11,767,600 |
| |
(iv) |
Shared power to dispose or to direct the disposition of: 2,410,802 |
(c) See Schedule VI, which is incorporated herein
by reference, describes the transactions by the Reporting Person in the Common Stock during the past sixty days.
(d) N/A
(e) N/A
| ITEM 7. |
MATERIAL TO BE FILED AS EXHIBITS |
Item 7 is hereby amended to add the following
exhibit:
SIGNATURES
After reasonable inquiry and to the best of my
knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: October 23, 2023
| By: | /s/ Jonathan Milner |
| | | Name: Jonathan Milner |
Schedule V
TRADING DATA
The following table sets forth all transactions in the Ordinary Shares
of the Issuer effected by the Reporting Person in the past 60 days. Except as otherwise noted below, all such transactions were purchases
or sales of Ordinary Shares effected in the open market and the table excludes commissions paid in per share prices.
| Reporting
Person |
Trade
Date |
Buy/Sell |
No.
of
Shares/
Quantity |
Unit
Cost/
Proceeds |
Security |
| Jonathan
Milner |
9/11/2023 |
Buy |
4,500 |
$22.8599 |
ADS |
| Jonathan
Milner |
9/12/2023 |
Buy |
4,500 |
$22.7899 |
ADS |
| Jonathan
Milner |
9/13/2023 |
Buy |
4,500 |
$22.8389 |
ADS |
| Jonathan
Milner |
9/14/2023 |
Buy |
4,500 |
$22.8172 |
ADS |
| Jonathan
Milner |
9/15/2023 |
Buy |
4,500 |
$22.8200 |
ADS |
| Jonathan
Milner |
9/18/2023 |
Buy |
4,500 |
$22.7244 |
ADS |
| Jonathan
Milner |
9/19/2023 |
Buy |
4,500 |
$22.6700 |
ADS |
| Jonathan
Milner |
9/20/2023 |
Buy |
4,500 |
$22.6500 |
ADS |
| Jonathan
Milner |
9/21/2023 |
Buy |
4,500 |
$22.6800 |
ADS |
| Jonathan
Milner |
9/22/2023 |
Buy |
4,500 |
$22.6000 |
ADS |
| Jonathan
Milner |
9/29/2023 |
Buy |
4,400 |
$22.6722 |
ADS |
| Jonathan
Milner |
9/29/2023 |
Buy |
4,400 |
$22.7461 |
ADS |
| Jonathan
Milner |
10/02/2023 |
Buy |
4,400 |
$22.6457 |
ADS |
| Jonathan
Milner |
10/09/2023 |
Buy |
4,500 |
$22.6700 |
ADS |
| Jonathan
Milner |
10/16/2023 |
Buy |
4,500 |
$22.7460 |
ADS |
Exhibit 99.25
Jonathan Milner
Issues Statement Responding to the Glass Lewis Report
Welcomes the
Glass Lewis report's observations on the disproportionate rewards for Abcam’s Executive Directors and on the identified issues
with peer group valuation strategies
Urges Shareholders
to continue to Vote AGAINST the current proposed acquisition of Abcam by Danaher
CAMBRIDGE, England,
23 October 2023 – Jonathan Milner, the founder and one of the largest investors in Abcam plc (“Abcam” or the “Company”)
(NYSE: ABCM) with ownership of 6.16% of the Company, has today issued the following statement in response to a 21 October 2023 report
from Glass Lewis. Jonathan Milner urges shareholders to continue to vote AGAINST the current proposed acquisition of Abcam by Danaher
Corporation (NYSE: DHR) or its affiliates (“Danaher”).
Commenting on the
report, Jonathan Milner issued the following statement:
“I
welcome Glass Lewis's scrutiny of the pressing issues surrounding excessive executive pay and bonuses, aspects also recently covered
in a Times article, as well as their critical examination of the peer group selection method used for Abcam's valuation. I
share these concerns, and these arrangements call for immediate attention.
As I have reiterated
on numerous occasions, I firmly believe that Danaher’s offer of $24 per share significantly undervalues Abcam, offering no premium
for control. When considering the potential of Abcam as an independent entity bolstered by an effective Board and Executive Leadership,
the proposed acquisition price falls significantly short of reflecting the Company’s inherent worth.
Furthermore,
I am convinced that the timing of the sale process is inopportune. Abcam stands on the cusp of realising the substantial returns from
its five-year plan with significant investments already made.
It is pertinent
to reference the recent acquisition of Olink by Thermo Fisher, a transaction that not only underscores the continued robustness of our
sector but also commanded an appropriate strategic premium of 74%. This specific deal demonstrates that high-quality assets are capable
of securing a substantial strategic premium in a change of control transaction, something the Board of Abcam seems to have failed to
achieve. This deficiency is set to result in an undue transfer of considerable value from Abcam’s shareholders to those of Danaher.
I believe that
voting AGAINST the transaction is, without question, in the best interest of shareholders. My commitment extends beyond restoring the
Company to its former stature as a premium-rated entity in the life sciences sector. The Board I envision for Abcam, comprising distinguished
and independent nominees, will maintain an unwavering dedication to maximising shareholder value.”
THE CHOICE
IS CLEAR– VOTE AGAINST THIS PROPOSED TRANSACTION AND SEND A CLEAR MESSAGE TO THE BOARD THAT THEY ARE DISSATISFIED WITH THE
PROPOSED ACQUISITION.
For more information,
please visit https://abcamfocus.com/
Jonathan Milner
https://abcamfocus.com/
Investor contact
Alliance Advisors (Europe)
T: +44 7733 265 198 / E: focusabcam@allianceadvisors.com
Michael Roper
Alliance Advisors (US)
T: +1 917 414 4766
Thomas Ball
Peel Hunt LLP
T: +44 (0) 20 7418 8900
Christopher Golden / James Steel
Sohail Akbar / Jock Maxwell Macdonald
International PR advisers
ICR Consilium (Europe)
T: +44 (0)20 3709 5700 / E: focusabcam@consilium-comms.com
Mary-Jane Elliott / Matthew Neal / Davide
Salvi
ICR (US)
T: +1 646 677 1811 / E: FocusAbcam@icrinc.com
Dan McDermott
IMPORTANT ADDITIONAL
INFORMATION
THIS DOCUMENT HAS
BEEN ISSUED BY DR. JONATHAN MILNER ("DR. MILNER").
DR. MILNER HAS
PUBLISHED A PROXY STATEMENT AND ACCOMPANYING WHITE PROXY CARD TO BE USED TO SOLICIT VOTES AGAINST THE PROPOSED ACQUISITION OF ABCAM PLC
(THE "COMPANY") BY DIADEM HOLDCO LIMITED, A WHOLLY OWNED INDIRECT SUBSIDIARY OF DANAHER CORPORATION, AT $24 PER SHARE, AT A
MEETING OF THE SHAREHOLDERS CONVENED PURSUANT TO THE COMPANIES ACT 2006 (THE “COURT MEETING”).
DR. MILNER STRONGLY
ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL
CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE MADE AVAILABLE AT NO CHARGE ONLINE ON THE WEBSITE OF THE U.S. SECURITIES
AND EXCHANGE COMMISSION AT WWW.SEC.GOV AND ON A WEBSITE HOSTED BY DR. MILNER TO PROVIDE INFORMATION TO SHAREHOLDERS ABOUT THE
COURT MEETING AT WWW.ABCAMFOCUS.COM. HOLDERS OF COMPANY SECURITIES ALSO SHOULD RECEIVE COPIES OF THE PROXY STATEMENT AND PROXY
CARD BY MAIL, AND COPIES WILL BE PROVIDED AT NO CHARGE UPON REQUEST MADE TO DR. MILNER’S PROXY SOLICITOR, ALLIANCE ADVISORS, BY
EMAIL TO FOCUSABCAM@ALLIANCEADVISORS.COM OR BY PHONE TO 877-777-8211 FROM NORTH AMERICA OR TO 0800-102- 6998 FROM ELSEWHERE.
THIS DOCUMENT IS
FOR DISCUSSION AND INFORMATIONAL PURPOSES ONLY. THE VIEWS EXPRESSED HEREIN REPRESENT THE OPINIONS OF DR. MILNER AS OF THE DATE HEREOF.
DR. MILNER RESERVES THE RIGHT TO CHANGE ANY OF HIS OPINIONS EXPRESSED HEREIN AT ANY TIME AND FOR ANY REASON AND EXPRESSLY DISCLAIMS ANY
OBLIGATION TO CORRECT, UPDATE OR REVISE THE INFORMATION CONTAINED HEREIN OR TO OTHERWISE PROVIDE ANY ADDITIONAL MATERIALS. SUBJECT TO
THE FOREGOING, AND AS SET FORTH BELOW, DR. MILNER INTENDS TO MAKE AVAILABLE AT AN APPROPRIATE TIME ADDITIONAL INFORMATION ABOUT THE COURT
MEETING INCLUDING HOW TO VOTE AT SUCH MEETING.
DR. MILNER HAS
INVESTMENTS IN THE COMPANY WHICH ARE DISCLOSED IN THE PROXY STATEMENT AND OTHER PROXY MATERIALS, AND CONSEQUENTLY HAS A FINANCIAL INTEREST
IN THE PROFITABILITY OF HIS POSITIONS IN THE COMPANY. ACCORDINGLY THIS DOCUMENT SHOULD NOT BE REGARDED AS IMPARTIAL. NOTHING IN THIS
DOCUMENT SHOULD BE TAKEN AS ANY INDICATION OF DR. MILNER 'S CURRENT OR FUTURE TRADING OR VOTING INTENTIONS AND/OR ACTIVITIES WHICH MAY
CHANGE AT ANY TIME.
CERTAIN INFORMATION
IN THIS DOCUMENT IS BASED ON PUBLICLY AVAILABLE INFORMATION WITH RESPECT TO THE COMPANY, INCLUDING PUBLIC FILINGS AND DISCLOSURES MADE
BY THE COMPANY AND OTHER SOURCES, AS WELL AS DR. MILNER'S ANALYSIS OF SUCH PUBLICLY AVAILABLE INFORMATION. DR. MILNER HAS RELIED UPON
AND ASSUMED, WITHOUT INDEPENDENT VERIFICATION, THE ACCURACY AND COMPLETENESS OF SUCH INFORMATION, AND NO REPRESENTATION OR WARRANTY IS
MADE THAT ANY SUCH DATA OR INFORMATION IS COMPLETE OR ACCURATE. DR. MILNER RECOGNISES THAT THERE MAY BE CONFIDENTIAL OR OTHERWISE NON-PUBLIC
INFORMATION WITH RESPECT TO THE COMPANY THAT COULD ALTER THE OPINIONS OF DR. MILNER WERE SUCH INFORMATION KNOWN.
NO REPRESENTATION,
WARRANTY OR UNDERTAKING, EXPRESS OR IMPLIED, IS GIVEN AND NO RESPONSIBILITY OR LIABILITY OR DUTY OF CARE IS OR WILL BE ACCEPTED BY DR.
MILNER CONCERNING: (I) THIS DOCUMENT AND ITS CONTENTS, INCLUDING WHETHER THE INFORMATION AND OPINIONS CONTAINED HEREIN ARE ACCURATE,
FAIR, COMPLETE OR CURRENT; (II) THE PROVISION OF ANY FURTHER INFORMATION, WHETHER BY WAY OF UPDATE TO THE INFORMATION AND OPINIONS CONTAINED
IN THIS DOCUMENT OR OTHERWISE TO THE RECIPIENT AFTER THE DATE OF THIS DOCUMENT; OR (III) THAT DR. MILNER'S INVESTMENT PROCESSES OR INVESTMENT
OBJECTIVES WILL OR ARE LIKELY TO BE ACHIEVED OR SUCCESSFUL OR THAT DR. MILNER'S INVESTMENTS WILL MAKE ANY PROFIT OR WILL NOT SUSTAIN
LOSSES. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TO THE FULLEST EXTENT PERMITTED BY LAW, DR. MILNER WILL NOT BE RESPONSIBLE
FOR ANY LOSSES, WHETHER DIRECT, INDIRECT OR CONSEQUENTIAL, INCLUDING LOSS OF PROFITS, DAMAGES, COSTS, CLAIMS OR EXPENSES RELATING TO
OR ARISING FROM THE RECIPIENT'S OR ANY PERSON'S RELIANCE ON THIS DOCUMENT.
EXCEPT FOR THE
HISTORICAL INFORMATION CONTAINED HEREIN, THE INFORMATION AND OPINIONS INCLUDED IN THIS DOCUMENT CONSTITUTE FORWARD-LOOKING STATEMENTS,
INCLUDING ESTIMATES AND PROJECTIONS PREPARED WITH RESPECT TO, AMONG OTHER THINGS, THE COMPANY'S ANTICIPATED OPERATING PERFORMANCE, THE
VALUE OF THE COMPANY'S SECURITIES, DEBT OR ANY RELATED FINANCIAL INSTRUMENTS THAT ARE BASED UPON OR RELATE TO THE VALUE OF SECURITIES
OF THE COMPANY (COLLECTIVELY, "COMPANY SECURITIES"), GENERAL ECONOMIC AND MARKET CONDITIONS AND OTHER FUTURE EVENTS. YOU SHOULD
BE AWARE THAT ALL FORWARD-LOOKING STATEMENTS, ESTIMATES AND PROJECTIONS ARE INHERENTLY UNCERTAIN AND SUBJECT TO SIGNIFICANT ECONOMIC,
COMPETITIVE, AND OTHER UNCERTAINTIES AND CONTINGENCIES AND HAVE BEEN INCLUDED SOLELY FOR ILLUSTRATIVE PURPOSES. ACTUAL RESULTS MAY DIFFER
MATERIALLY FROM THE INFORMATION CONTAINED HEREIN DUE TO REASONS THAT MAY OR MAY NOT BE FORESEEABLE. THERE CAN BE NO ASSURANCE THAT THE
COMPANY SECURITIES WILL TRADE AT THE PRICES THAT MAY BE IMPLIED HEREIN, AND THERE CAN BE NO ASSURANCE THAT ANY ESTIMATE, PROJECTION OR
ASSUMPTION HEREIN IS, OR WILL BE PROVEN, CORRECT.
THIS DOCUMENT DOES
NOT CONSTITUTE (A) AN OFFER OR INVITATION TO BUY OR SELL, OR A SOLICITATION OF AN OFFER TO BUY OR SELL, ANY SECURITY OR OTHER FINANCIAL
INSTRUMENT AND NO LEGAL RELATIONS SHALL BE CREATED BY ITS ISSUE, (B) A "FINANCIAL PROMOTION" FOR THE PURPOSES OF THE FINANCIAL
SERVICES AND MARKETS ACT 2000, (C) "INVESTMENT ADVICE" AS DEFINED BY THE FCA HANDBOOK, (D) "INVESTMENT RESEARCH"
AS DEFINED BY THE FCA HANDBOOK, OR (E) AN "INVESTMENT RECOMMENDATION" AS DEFINED BY REGULATION (EU) 596/2014 AND BY REGULATION
(EU) NO. 596/2014 AS IT FORMS PART OF U.K. DOMESTIC LAW BY VIRTUE OF SECTION 3 OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("EUWA
2018") INCLUDING AS AMENDED BY REGULATIONS ISSUED UNDER SECTION 8 OF EUWA 2018. THIS DOCUMENT IS NOT (AND MAY NOT BE CONSTRUED TO
BE) LEGAL, TAX, INVESTMENT, FINANCIAL OR OTHER ADVICE. EACH RECIPIENT SHOULD CONSULT THEIR OWN LEGAL COUNSEL AND TAX AND FINANCIAL ADVISERS
AS TO LEGAL AND OTHER MATTERS CONCERNING THE INFORMATION CONTAINED HEREIN. THIS DOCUMENT DOES NOT PURPORT TO BE ALL-INCLUSIVE OR TO CONTAIN
ALL OF THE INFORMATION THAT MAY BE RELEVANT TO AN EVALUATION OF THE COMPANY, COMPANY SECURITIES OR THE MATTERS DESCRIBED HEREIN.
NO AGREEMENT, COMMITMENT,
UNDERSTANDING OR OTHER LEGAL RELATIONSHIP EXISTS OR MAY BE DEEMED TO EXIST BETWEEN OR AMONG DR. MILNER AND ANY OTHER PERSON BY VIRTUE
OF FURNISHING THIS DOCUMENT. DR. MILNER IS NOT ACTING FOR OR ON BEHALF OF, AND IS NOT PROVIDING ANY ADVICE OR SERVICE TO, ANY RECIPIENT
OF THIS DOCUMENT. DR. MILNER IS NOT RESPONSIBLE TO ANY PERSON FOR PROVIDING ADVICE IN RELATION TO THE SUBJECT MATTER OF THIS DOCUMENT.
BEFORE DETERMINING ON ANY COURSE OF ACTION, ANY RECIPIENT SHOULD CONSIDER ANY ASSOCIATED RISKS AND CONSEQUENCES AND CONSULT WITH ITS
OWN INDEPENDENT ADVISORS AS IT DEEMS NECESSARY.
DR. MILNER HAS
NOT SOUGHT OR OBTAINED CONSENT FROM ANY THIRD PARTY TO USE ANY STATEMENTS OR INFORMATION CONTAINED HEREIN. ANY SUCH STATEMENTS OR INFORMATION
SHOULD NOT BE VIEWED AS INDICATING THE SUPPORT OF SUCH THIRD PARTY FOR THE VIEWS EXPRESSED HEREIN. ALL TRADEMARKS AND TRADE NAMES USED
HEREIN ARE THE EXCLUSIVE PROPERTY OF THEIR RESPECTIVE OWNERS.
Abcam (NASDAQ:ABCM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abcam (NASDAQ:ABCM)
Historical Stock Chart
From Apr 2023 to Apr 2024
